At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.
Jeffrey L. Goldberg, MD, PhD
Advertisement
Jeffrey L. Goldberg, MD, PhD, is professor and chair of the Department of Ophthalmology at Byers Eye Institute at Stanford University.
Articles by Jeffrey L. Goldberg, MD, PhD
Findings from basic science research elucidating the mechanisms of retinal ganglion cell axon degeneration, regeneration, and death have identified new therapeutic targets for glaucoma that are being investigated in preclinical and clinical studies.
Advertisement
Latest Updated Articles
- Therapeutic advances in glaucoma focus on retinal ganglion cell pathology
Published: August 1st 2015 | Updated:
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
3
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
4
AAO 2025: Diana Do, MD, reviews the real-world use of aflibercept 8 mg
5
.png "Optometry Times"){kind=logo}
